Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-Resistant Major Depressive Disorder Clear all
Withdrawn Phase 2 Interventional

Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder

NCT05652465
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Not yet recruiting Phase 3 Interventional

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

NCT01234558
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Jul 22, 2026, 3:57 PM EDT
Recruiting Phase 1 Interventional

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

NCT03973268
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Major Depression
Interventions
Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions
Device · Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression

NCT01431001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Device
Lead sponsor
Cervel Neurotech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Targeting IL-17A for Treatment-Resistant Depression

NCT04979910
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ixekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation for Treatment Resistant Depression

NCT00367003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Jul 22, 2026, 3:57 PM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

NCT02356107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jul 22, 2026, 3:57 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
VLS-01-203 BU, VLS-01-BU Placebo
Drug
Lead sponsor
atai Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Lamotrigine Augmentation in Resistant Depression

NCT00901407
View directory record Official record
Conditions
Unipolar Depression
Interventions
lamotrigine, placebo, paroxetine
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 12, 2009 · Synced Jul 22, 2026, 3:57 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

NCT05172271
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions
MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation
Device · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
25 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
MIJ821, Placebo, Ketamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 22, 2026, 3:57 PM EDT
Recruiting Not applicable Interventional

RESISTance Exercise for Depression Trial

NCT06110897
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
High Dose Resistance Exercise Training, Low Dose Resistance Exercise Training Group
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Ames, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Active, not recruiting Phase 2 Interventional

Mindfulness Engaged Neurostimulation for Depression

NCT06399406
View directory record Official record
Conditions
Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Interventions
Medi-TBS
Combination Product
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NCT03283670
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
Nitrous Oxide 25%, Nitrous Oxide 50%, Placebo Gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 22, 2026, 3:57 PM EDT
Terminated Phase 1 Interventional

Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder

NCT00380042
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Cortical Stimulation, Sham
Device
Lead sponsor
Northstar Neuroscience
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

NCT02900092
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ganaxolone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 22, 2026, 3:57 PM EDT
Terminated Phase 2 Interventional Results available

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

NCT04821271
View directory record Official record
Conditions
Major Depressive Disorder, Treatment-Resistant Depression, Depression
Interventions
Placebo, TS-161
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

NCT02452892
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
Interventions
LFMS
Device
Lead sponsor
Tal Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Garden Grove, California • Lemon Grove, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 22, 2026, 3:57 PM EDT
Active, not recruiting Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 3:57 PM EDT
Withdrawn Phase 2 Interventional

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

NCT05381974
View directory record Official record
Conditions
Treatment-Resistant Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 22, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

AZD6765 for Treatment Resistant Depression

NCT00491686
View directory record Official record
Conditions
Depression
Interventions
AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Glendale, California • Hartford, Connecticut • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2011 · Synced Jul 22, 2026, 3:57 PM EDT